Targets › PLAUR
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.
GPI-anchored receptor that recruits and activates the urokinase-type plasminogen activator (uPA) at the cell surface. Activated uPA converts plasminogen into plasmin, initiating extracellular matrix degradation and remodeling. (UniProt, Q03405)
Open in Phaseline: the race on PLAUR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Curasight | 64Cu-DOTA-AE105 uPAR-targeting PET imaging agent; copper-64 labeled peptide for PET imaging of uPAR-expres | PLAUR | Phase 2 | Prostate Cancer | Jan 2027 |
| Adcendo ApS | ADCE-D01 anti-uPARAP antibody conjugated to topoisomerase I inhibitor via protease-cleavable linker | PLAUR | Phase 1 | Metastatic Soft Tissue Sarcoma | Feb 2029 |
Prostate Cancer (1) Metastatic Soft Tissue Sarcoma (1)
small molecule (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.